Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Blueprint Medicines Corporation (BPMC) stocks in Canada

Learn how to easily invest in Blueprint Medicines Corporation stocks.

Blueprint Medicines Corporation is a biotechnology business based in the US. Blueprint Medicines Corporation stocks (BPMC.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $90.82 – a decrease of 11.65% over the previous week. Blueprint Medicines Corporation employs 476 staff and has a trailing 12-month revenue of around $107.2 million.

How to buy shares in Blueprint Medicines Corporation

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – BPMC – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Blueprint Medicines Corporation stock price (NASDAQ:BPMC)

Use our graph to track the performance of BPMC stocks over time.

Blueprint Medicines Corporation shares at a glance

Information last updated 2022-01-17.
Latest market close$68.91
52-week range$74.75 - $117.86
50-day moving average $102.61
200-day moving average $96.16
Wall St. target price$120.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-7.12

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Blueprint Medicines Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Blueprint Medicines Corporation price performance over time

Historical closes compared with the close of $68.91 from 2022-01-21

1 week (2022-01-14) -11.65%
1 month (2021-12-22) -36.57%
3 months (2021-10-22) -32.63%
6 months (2021-07-22) -19.31%
1 year (2021-01-22) -32.01%
2 years (2020-01-22) -1.30%
3 years (2019-01-22) 3.38%
5 years (2017-01-20) 113.28%

Is Blueprint Medicines Corporation under- or over-valued?

Valuing Blueprint Medicines Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Blueprint Medicines Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Blueprint Medicines Corporation's EBITDA

Blueprint Medicines Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $345.2 million.

The EBITDA is a measure of a Blueprint Medicines Corporation's overall financial performance and is widely used to measure a its profitability.

Blueprint Medicines Corporation financials

Revenue TTM $107.2 million
Gross profit TTM $466.5 million
Return on assets TTM -16.96%
Return on equity TTM -32.03%
Profit margin 0%
Book value $21.20
Market capitalisation $4.6 billion

TTM: trailing 12 months

Blueprint Medicines Corporation share dividends

We're not expecting Blueprint Medicines Corporation to pay a dividend over the next 12 months.

Blueprint Medicines Corporation share price volatility

Over the last 12 months, Blueprint Medicines Corporation's shares have ranged in value from as little as $74.75 up to $117.86. A popular way to gauge a stock's volatility is its "beta".

BPMC.US volatility(beta: 0.72)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Blueprint Medicines Corporation's is 0.7172. This would suggest that Blueprint Medicines Corporation's shares are less volatile than average (for this exchange).

Blueprint Medicines Corporation overview

Blueprint Medicines Corporation, a precision therapy company, develops medicines for people with cancer and hematologic disorders, and multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy in the United States and Europe. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and fisogatinib, an orally available and potent inhibitor, which is in Phase 1b/2 trials for the treatment of advanced hepatocellular carcinoma. It is also developing pralsetinib for the treatment of RET-altered non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945, a selective and potent investigational inhibitors of double-mutant EGFR harboring, which are in preclinical stage for patient with EGFR-driven NSCLC. In addition, the company is developing BLU-782, an oral and investigational activin-like kinase 2 inhibitor, which is in Phase I clinical trials for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc. ; CStone Pharmaceuticals; Genentech, Inc. ; and F.

Stocks similar to Blueprint Medicines Corporation

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site